Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19
EQS-News: Atriva Therapeutics GmbH / Key word(s): Study results/Research UpdateAtriva Therapeutics announces Topline Results from the Proof of Concept (POC)...